LENZ Therapeutics (LENZ) Q2 2024 earnings summary

Executive summary

• Achieved public market debut via reverse merger, submitted NDA to FDA for LNZ100 for presbyopia, and completed $30M PIPE financing in July 2024.

• LNZ100, a once-daily eye drop, met all primary and key secondary endpoints in Phase 3 CLARITY trials, showing rapid, durable near vision improvement and strong safety profile.

• NDA submission in August 2024 is supported by robust clinical, manufacturing, and quality data; FDA approval and US commercial launch targeted for H2 2025.

• Pro forma cash and equivalents at $226.2M as of June 30, 2024, extending runway to post-launch positive cash flow.

• Focused on a $3B+ US presbyopia market opportunity with limited pharmacologic competition.

Financial highlights

• Ended Q2 2024 with $196.1M in cash, cash equivalents, and marketable securities; pro forma $226.2M including July PIPE financing.

• Q2 2024 net loss was $10.3M ($0.40 per share), down from $14.7M ($7.53 per share) in Q2 2023, reflecting increased share count post-merger.

• R&D expenses dropped to $6.9M in Q2 2024 from $12.6M in Q2 2023, reflecting completion of Phase 3 trials.

• SG&A expenses rose to $7.4M in Q2 2024 from $2.3M in Q2 2023, driven by commercial team buildout and pre-commercial activities.

• Other income, net, was $4.1M in Q2 2024, mainly from higher interest income and fair value adjustments.

Outlook and guidance

• FDA approval for LNZ100 anticipated by mid-2025, with US commercial launch possible in H2 2025.

• Cash runway expected to fund operations through post-launch positive operating cash flow.

• SG&A expected to ramp further in 2024 and 2025 as commercialization nears.

• R&D expenses projected to decline further as focus shifts to pre-approval manufacturing.

• No revenue expected from product sales until regulatory approval and launch.